Therapeutic Solutions International Inc (TSOI)

[BigBadWolf]

why would Dixon change now, just because of a Phase III Trial awaiting hopefully an approved amendment by the FDA that would enhance enrollment (shall we say ????)

(e) Use of Proceeds. The Company will use the net proceeds from the offering for any corporate purpose at the sole discretion of the Company.

Subject: FILE NO S7-24-20.
From: Tim Dixon
Affiliation:
Feb. 05, 2021

To Whom It May Concern,

The Company I run, Therapeutic Solutions International, Inc. (TSOI) has relied upon the availability of convertible debentures with the utilization of rule 144 as a means of financing the operations of TSOI. Had this not been available I would not have been able to advance the Company otherwise and most likely would not have been able to stay fully reporting. The loss of such instruments would be devastating to smaller companies like TSOI who cannot attract the big investment bankers the big boards keep in their pockets like loose change. Please consider carefully the impact this will have upon innovation and new technologies coming to market to benefit all of humanity.

Sincerely yours,

Timothy G Dixon, President & CEO
Therapeutic Solutions International, Inc.

https://www.sec.gov/comments/s7-24-20/s72420-228879.htm



https://www.otcmarkets.com/stock/TSOI/disclosure

pick any financials or just look @ the latest

https://www.otcmarkets.com/filing/html?id=16030841&guid=mr--kF6afPifJth
https://www.otcmarkets.com/filing/html?id=16088583&guid=ImX-kekfFudqJth#ex99-1_htm

Note 8 – Convertible Notes Payable

At various times during the six months ended June 30, 2022, the Company entered into convertible promissory notes with principal amounts totaling $337,500 with a third party for which the proceeds were used for operations. The Company received net proceeds of $315,000, and a $22,500 original issuance discount was recorded. The convertible promissory notes incur interest at rates from 10% to 12% per annum and mature on dates ranging from January 1, 2023 to June 27, 2023. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at June 30, 2022 a total of 167,223,808 common shares in connection with these promissory notes.

Bids still in for any discounted shares available for sale below 01